Skip to main content
Top
Published in: Rheumatology International 8/2007

01-06-2007 | Original Article

Factors affecting drug treatment compliance in patients with rheumatoid arthritis

Authors: Reyhan Tuncay, Emel Eksioglu, Banu Cakir, Eda Gurcay, Aytul Cakci

Published in: Rheumatology International | Issue 8/2007

Login to get access

Abstract

We prospectively examined 100 rheumatoid arthritis (RA) patients to calculate drug compliance rates, characteristics of compliant and non-compliant patients, and changes in compliance over time. Three assessments were obtained over a one-year follow–up. Detailed drug history of RA and for concomitant disease was queried. Sedimentation rate, C-reactive protein, and rheumatoid factor values, Ritchie articular index, morning stiffness, and health assessment questionnaire were evaluated. Twenty-six patients (30.2%) were consistently compliant and 10 patients (11.6%) were consistently non-compliant. Older age was associated with a greater likelihood of compliance. Comparison of compliant and non-compliant groups revealed no statistically significant difference in distribution of gender, disease duration, and total number of pills taken for RA and/or total number of pills taken for any reason. In conclusion, compliance to drugs in RA patients is a common problem. Clinical and laboratory activity of RA had less influence on drug compliance. Older age is associated with a greater likelihood of compliance.
Literature
1.
go back to reference Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA (2000) Measuring adherence to behavioral and medical interventions. Control Clin Trials 21:188S–194SPubMedCrossRef Vitolins MZ, Rand CS, Rapp SR, Ribisl PM, Sevick MA (2000) Measuring adherence to behavioral and medical interventions. Control Clin Trials 21:188S–194SPubMedCrossRef
2.
go back to reference Viller F, Guillemin F, Briancon S, Moum T, Suurmeijer T, van den Heuvel W (1999) Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol 26:2114–2122PubMed Viller F, Guillemin F, Briancon S, Moum T, Suurmeijer T, van den Heuvel W (1999) Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study. J Rheumatol 26:2114–2122PubMed
3.
go back to reference de Klerk E, van der Heide D, Landewe R, van der Tempel H, Urquart J, van der Linden S (2003) Patient compliance in rheumatoid arthritis, polymyalgia rheumatica and gout. J Rheumatol 30:44–54PubMed de Klerk E, van der Heide D, Landewe R, van der Tempel H, Urquart J, van der Linden S (2003) Patient compliance in rheumatoid arthritis, polymyalgia rheumatica and gout. J Rheumatol 30:44–54PubMed
4.
go back to reference Pullar T, Peaker S, Martin MF, Bırd HA, Feely MP (1988) The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapy. Br J Rheumatol 27:381–384PubMedCrossRef Pullar T, Peaker S, Martin MF, Bırd HA, Feely MP (1988) The use of a pharmacological indicator to investigate compliance in patients with a poor response to antirheumatic therapy. Br J Rheumatol 27:381–384PubMedCrossRef
5.
go back to reference Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G (1993) Is this patient taking the treatment as prescribed? JAMA 269:2779–2781PubMedCrossRef Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G (1993) Is this patient taking the treatment as prescribed? JAMA 269:2779–2781PubMedCrossRef
6.
go back to reference Lee P, Tan LJ (1979) Drug compliance in outpatients with rheumatoid arthritis. Aust N Z J Med 9:274–277PubMed Lee P, Tan LJ (1979) Drug compliance in outpatients with rheumatoid arthritis. Aust N Z J Med 9:274–277PubMed
7.
go back to reference Kauppi M, Sokka T, Hannonen P (2005) Survey nonresponse is associated with increased mortality in patients with rheumatoid arthritis and in a community population. J Rheumatol 32:807–810PubMed Kauppi M, Sokka T, Hannonen P (2005) Survey nonresponse is associated with increased mortality in patients with rheumatoid arthritis and in a community population. J Rheumatol 32:807–810PubMed
8.
go back to reference Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, O’Malley KJ, Janssen NM, Marcus DM, Tagore J, Svarez-Almazor ME (2005) Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic diseases. J Rheumatol 32:913–919PubMed Garcia Popa-Lisseanu MG, Greisinger A, Richardson M, O’Malley KJ, Janssen NM, Marcus DM, Tagore J, Svarez-Almazor ME (2005) Determinants of treatment adherence in ethnically diverse, economically disadvantaged patients with rheumatic diseases. J Rheumatol 32:913–919PubMed
9.
go back to reference Blackwell B (1972) The drug defaulter. Clin Pharmacol Ther 13:841–848PubMed Blackwell B (1972) The drug defaulter. Clin Pharmacol Ther 13:841–848PubMed
10.
go back to reference Owen SG, Friesen WT, Roberts MS, Flux W (1985) Determinants of compliance in rheumatoid arthritic patients assessed in their home environment. Br J Rheumatol 24:313–320PubMedCrossRef Owen SG, Friesen WT, Roberts MS, Flux W (1985) Determinants of compliance in rheumatoid arthritic patients assessed in their home environment. Br J Rheumatol 24:313–320PubMedCrossRef
Metadata
Title
Factors affecting drug treatment compliance in patients with rheumatoid arthritis
Authors
Reyhan Tuncay
Emel Eksioglu
Banu Cakir
Eda Gurcay
Aytul Cakci
Publication date
01-06-2007
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 8/2007
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-006-0299-9

Other articles of this Issue 8/2007

Rheumatology International 8/2007 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine